Navigation Links
Discovery of mechanisms predicting response to new treatments in colon cancer
Date:5/20/2012

Barcelona, 20 May 2012. The Stem Cells and Cancer Research Group headed by Dr Hctor G. Palmer at the Vall d'Hebrn Institute of Oncology (VHIO) has identified the molecular mechanisms that determine patients' response to certain drugs used in clinical trials for colon cancer treatment. The study led by VHIO also benefited from the collaboration with Professor Alberto Muozs laboratory at the Instituto de Investigaciones Biomedicas Alberto Sols, Consejo Superior de Investigaciones Cientficas (IIB-CSIC-Madrid). Published today in Nature Medicine, this work identifies biomarkers that predict response to treatment and proposes therapeutic solutions for patients who do not respond well. These advances will guide better selection of treatments and avoid the risk of administering ineffective drugs.

Colon cancer is a disease caused by a malignant tumour in the large intestine. When detected early the tumor is removed through surgery and patients are treated with adjuvant chemotherapy, eliminating the disease in the majority of cases. However, in advanced stages, colon tumours are resistant to a broad spectrum of anti-tumour drugs and cancerous cells escape treatment and disseminate around the body, giving rise to metastasis. Currently there are no effective treatments to halt the progression of colon cancer in these later stages and most patients die as a result of disease progression.

Over recent years new drugs have been designed to target and block the activity of certain molecules responsible for promoting tumor growth and metastasis. Some of these, which are currently in clinical trials, are showing promising results in certain patients, while others show no improvement at all. This study headed by the VHIO examines the differential response to treatment and was supported by the Olga Torres Foundation (FOT), the Scientific Foundation of the Spanish Association Against Cancer (AECC), and the Carlos III Institute of Health (ISCIII).


'/>"/>
Contact: Amanda Wren
awren@vhio.net
34-695-207-886
Vall dHebron Institute of Oncology
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. DNA barcoding verified the discovery of a highly disconnected crane fly species
2. Understanding the RNAi Reagents Market Overlap with Drug Discovery and Therapeutic Development is Critical for Pharmaceutical Leaders
3. Discovery of plant proteins may boost agricultural yields and biofuel production
4. Discovery of a new family of key mitochondrial proteins for the function and viability of the brain
5. Bacteria discovery could lead to antibiotics alternatives
6. Discovery reveals chromosomes organize into yarns
7. Stomata development in plants unraveled -- a valuable discovery for environmental research
8. New discovery may lead to effective prevention and treatment of graft-versus-host dsease
9. Tales from the crypt lead researchers to cancer discovery
10. Breast cancer risk gene discovery fast tracked by new technology
11. Discovery offers insight into treating viral stomach flu
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/15/2014)... German Gauß-Allianz has admitted Johannes Gutenberg University Mainz ... Rhineland-Palatinate science hub continues to maintain a significant ... , "The acceptance of Johannes Gutenberg University ... is a milestone in the national and international ... The state of Rhineland-Palatinate can be proud that ...
(Date:10/15/2014)... SHELTON, Conn. , Oct. 15, 2014 NXT-ID, Inc. ... a biometric authentication company focused on the growing mobile commerce market ... NASDAQ MarketSite in Times Square on Monday October 13 th . ... with CTO David Tunnel and angel investor Mr. ... Gino Pereira , CEO of NXT-ID thanked his investors and employees ...
(Date:10/14/2014)... discriminating thieves, prostate cancer tumors scavenge and hoard copper ... such avarice may be a fatal weakness. , ... kill prostate cancer cells by delivering a trove of ... diseased cells brimming with the mineral, leaving non-cancer cells ... already commercially available for other uses, could soon be ...
Breaking Biology News(10 mins):Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 2Johannes Gutenberg University Mainz joins Germany's Gauss-Allianz as a full member 3Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Prostate cancer's penchant for copper may be a fatal flaw 2
... exposure, serving size and parental behavior are the key drivers ... discussion at the 2013 Institute of Food Technologists (IFT) Annual ... standing-room only crowd of more than 200 conference attendees heard ... what their eating behaviors are and how the industry and ...
... approved to treat multiple sclerosis may also hold promise for ... that often leads to heart failure, researchers at the University ... findings are published in the July 16 issue of ... thickening of the heart muscle that shrinks the interior ...
... have taken part in an international study which has revealed ... in one of the most hostile environments on earth. ... Tibetan plateau, the largest high-altitude land mass in the world. ... genome which reveal how it copes with the extreme living ...
Cached Biology News:Taste rules for kids and healthy food choices 2MS drug shows promise for preventing heart failure 2Genetic secrets of the world's toughest little bird 2Genetic secrets of the world's toughest little bird 3
(Date:10/22/2014)... 2014 Involution Studios , a ... a new infographic, Understanding Ebola . The ... designed, easy to follow informative tool for anyone wanting ... symptoms and prevention. , "As the news has spread ... Ebola outbreak represents not only a healthcare crisis with ...
(Date:10/22/2014)... October 22, 2014 Physicians Choice ... cardiovascular pharmacogenetics menu, which enables healthcare providers to ... With PCLS’s evidence-based results, healthcare providers are better ... their therapy, while minimizing risks for adverse drug ... according to the FDA [1] more than 2.2 ...
(Date:10/22/2014)... 22, 2014 Nuvilex, Inc. (OTCQB: NVLX) – ... people worldwide are living with diabetes, with  that number ... The global market for diabetes treatments is approximately $500 ... worldwide died from pancreatic cancer.  Pancreatic cancer is the ... in the United States , and ...
(Date:10/20/2014)... , Oct. 20, 2014 Mapp ... experimental ZMapp™ antibody therapeutic to fight the Ebola ... difficult and time-consuming the production of pharmaceuticals can ... research publisher said that while some may be ... this compound, those with industry knowledge are well ...
Breaking Biology Technology:Involution Studios' Ebola Infographic Provides Key Disease Information and Statistics at a Glance 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 2PCLS Announces Expansion of Cardiovascular Pharmacogenetic Testing Menu 3Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3
... Paris: FR0005175080) announces promising preliminary data from,the Phase ... an adjunct to first line chemotherapy in patients ... on-going trial is a randomized, open label and ... in combination with cisplatin and,gemcitabine compared to the ...
... BRIDGEWATER, New Jersey and BIRMINGHAM, Alabama,Jan. 10 ... a,leading international scientific and regulatory consulting firm with,specialized ... Food &,Nutrition, Chemicals and Agriculture, Biotech & Consumer ... the new name for their,Pharmaceutical & Healthcare Division., ...
... Essilor,of America, Essilor International,s US subsidiary, has strengthened ... the acquisition,of Interstate Optical Co., one of the ... Mansfield, Ohio and,Indianapolis, Indiana serve eye care professionals ... US$26 million and 210 employees., Present for ...
Cached Biology Technology:Transgene's Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer 2Transgene's Therapeutic Vaccine TG4010 Shows Promising Preliminary Phase IIb Data in Advanced Non-Small Cell Lung Cancer 3Cantox Announces the Launch of Ashuren Health Sciences Pharmaceutical Division 2
...
Mouse anti-JNK (PT183/185) Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Acetyl CoA Carboxylase Antibody...
mu Opioid Receptor splice variant Immunogen: Synthetic peptide corresponding to residues K S C M D R G M R N L L P D D G P R Q E of Mu Opioid Receptor. Storage: -20 C, Avoid Freeze/Thaw Cycle...
Biology Products: